AC-262

• Dry-fill capsules (15 mg, 60 count, 900 mg total)
• 30 mL liquid solution (30 mg/mL, 900 mg total)
• 1 g powder

AC-262 is evaluated as a selective androgen receptor ligand in laboratory research. Common areas of mechanistic investigation include: Because SARM pharmacology is highly model-dependent, mechanistic attribution generally requires structured comparator groups and standardized endocrine-monitoring protocols.

• Androgen receptor activation: Studied for its ability to bind androgen receptors and influence androgen-responsive gene transcription under controlled experimental conditions
• Tissue-selective signaling: Investigated for preferential signaling profiles in certain preclinical models, typically compared with non-selective androgen receptor agonists
• Muscle protein synthesis: Explored in standardized training and unloading models examining hypertrophy-related signaling and muscle maintenance
• Bone biology: Studied in research evaluating bone turnover, mineral density, and skeletal remodeling endpoints
• Comparative androgenic activity: Assessed using prostate-associated biomarkers and other androgen-sensitive tissue endpoints in animal models

AC-262 is commonly studied in

• Skeletal-muscle hypertrophy and maintenance models
• Disuse-atrophy and muscle-wasting research
• Bone-density and bone-turnover studies
• Androgen receptor selectivity comparisons between skeletal muscle and androgen-sensitive tissues
• Metabolic and body-composition research with standardized dietary and activity variables
• Combination studies evaluating multiple anabolic or nutrient-partitioning interventions

Reported observations are model- and exposure-dependent and may include

• Suppression-like findings involving hypothalamic-pituitary-gonadal (HPG) axis biomarkers, consistent with androgen receptor agonist feedback
• Alterations in lipid biomarkers, commonly monitored through HDL- and LDL-related endpoints during longer-duration studies
• Sleep-disruption, irritability-like, or overstimulation-like findings in certain experimental models
• Elevations in hepatic-enzyme biomarkers during some oral-exposure paradigms, particularly when combined with other hepatically metabolized compounds
• Confounded interpretation when combined with additional SARMs, prohormones, or other endocrine-active comparator compounds

AC-262 is often explored alongside interventions that overlap with androgenic and performance-related pathways.